Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURVIVE: Levosimendan vs Dobutamine in Acute Heart Failure
NCT00348504Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levosimendan in Acute Heart Failure (AHF) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: All-cause mortality in the 180 days following randomization. Started Mar 2003; status: completed.
02
Drugs
levosimendan
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT00348504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00348504.